Abstracts tagged "drug therapy"

Abstract Number: 107 • 2016 ACR/ARHP Annual Meeting
Improvement of Quality and Cost-Effectiveness of Rheumatology Care By Creating Long-Term Alliances with Pharmaceutical Companies
M Van Houdenhoven (CEO, PhD, Prof)¹, F.H.J. van den Hoogen (MD, PhD, Prof)², K Bevers (MD, PhD)², W.H. van der Laan (MD, PhD)², J Van der Werf², M Staub³ and B.J.F. Van den Bemt (PharmD, PhD)⁴, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³Purchasing department, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Department of Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Biological therapies have importantly contributed to controlling disease activity in patients with inflammatory rheumatic diseases. As the high costs of biologics are a threat…
Abstract Number: 576 • 2015 ACR/ARHP Annual Meeting
Possibility of Extension of the Administration Interval of Tocilizumab in the Treatment of Rheumatoid Arthritis
Masao Sato¹ and Masao Takemura², ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Matsunami Reserch Park, Gifu, Japan
Background/Purpose: Biologics constitute an important drug category in the pharmacological treatment of rheumatoid arthritis (RA). Drug-free remission (REM) may also be achievable if the condition…
Abstract Number: 3088 • 2015 ACR/ARHP Annual Meeting
Genome Wide Expression Analyses Reveal Potentially Novel Drug Targets in Fibromyalgia
Kim Jones¹, Robert Bennett^2,3 and Sunil Kurian⁴, ¹Rsch & Develop/Mail Code SN OR, Oregon Health Sciences Univ, Portland, OR, ²SN-Office of Research & Development, Oregon Health & Science Univ, Portland, OR, ³Medicine & Nursing, Oregon Health & Science Univ, Portland, OR, ⁴The Scripps Research Institute, La Jolla, CA
Background/Purpose: Currently there are three drugs approved by the FDA for the treatment of fibromyalgia (FM), and there appears to be a paucity of drugs…
Abstract Number: 2362 • 2014 ACR/ARHP Annual Meeting
Enhanced Efficacy of Dexamethose with Synovial Fibroblast Targeted Micelles in a Collagen-Induced Arthritis Mouse Model
Rebecca A. Bader, David R. Wilson, Arundhati Ramani and Patricia R. Wardwell, Biomedical & Chemical Engineering, Syracuse University, Syracuse, NY
Background/Purpose: A number of conventional, disease modifying anti-rheumatic drugs (DMARDs) are associated with severe side effects due to non-specific targeting and impaired immune function. To…
Abstract Number: 1594 • 2014 ACR/ARHP Annual Meeting
Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis
Doquyen H. Huynh¹, Carol J. Etzel^2,3, Vanessa Cox⁴, Philip J. Mease⁵ and Arthur Kavanaugh⁶, ¹Rheumatology, UC San Diego School of Medicine, San Diego, CA, ²PO Box 786, Corrona, LLC., Southborough, MA, ³Department of Epidemiology, UT MD Anderson, Houston, TX, ⁴CORRONA, Inc, Southborough, MA, ⁵CORRONA, Seattle, WA, ⁶UCSD School of Medicine, La Jolla, CA
Background/Purpose: The increased use of tumor necrosis factor inhibitors (TNFi) has improved clinical outcomes for psoriatic arthritis (PsA) patients and made low disease activity (LDA)…
Abstract Number: 636 • 2014 ACR/ARHP Annual Meeting
Liposomal-Glucocorticoids: A Novel Approach to the Therapy of SLE
Yaakov Naparstek¹, Eli Moallem², Rina Ulmansky³, Erez Koren³ and Yechezkel Barenholz³, ¹Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel, ²Dept. of Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel, ³Hadassah - Hebrew University Medical Center, Jerusalem, Israel
Background/Purpose Glucocorticoids (GCs) have been known for years to be the most effective therapy in SLE. Their use is however limited by the need of…
Abstract Number: 1707 • 2013 ACR/ARHP Annual Meeting
Biological Insights From Genetics Of Rheumatoid Arthritis Contribute To Drug Discovery
Yukinori Okada^1,2,3, Di Wu^2,4,5,6, Chikashi Terao^7,8, Katsunori Ikari⁹, Yuta Kochi¹⁰, Koichiro Ohmura¹¹, Akari Suzuki¹⁰, Hisashi Yamanaka⁹, Joshua C. Denny¹², Jeffrey D. Greenberg¹³, Robert R. Graham¹⁴, Matthew A. Brown¹⁵, Sang-Cheol Bae¹⁶, Jane Worthington¹⁷, Leonid Padyukov¹⁸, Lars Klareskog¹⁹, Peter K. Gregersen²⁰, Peter M. Visscher^21,22, Katherine A. Siminovitch^23,24 and Robert M. Plenge²⁵, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Broad Institute, Cambridge, MA, ⁴Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA, ⁵Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, ⁶Department of Statistics, Harvard University, Cambridge, MA, ⁷Center for Genomic Medicine, Kyoto University, Kyoto, Japan, ⁸Department of Rheumatology and Clinical immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁰Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ¹¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹²Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, ¹³Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ¹⁴ITGR Human Genetics, Genentech, Inc., South San Francisco, CA, ¹⁵Human Genetics Group, The University of Queensland Diamantina Insititute, Brisbane, Australia, ¹⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁷Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ¹⁸Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²⁰Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²¹The University of Queensland Diamantina Institute, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia, ²²Queensland Brain Institute, The University of Queensland, St Lucia, Brisbane, Australia, ²³Mount Sinai Hospital, Toronto, ON, Canada, ²⁴University of Toronto, Toronto, ON, Canada, ²⁵Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: A major challenge in human genetics is to devise a systematic strategy to integrate disease-associated variants with diverse genomic and biological datasets to provide…
Abstract Number: 1555 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Drug Survival In Psoriatic Arthritis Patients Treated In Ordinary Clinical Practice
Glenn Haugeberg¹, Andreas P. Diamantopoulos¹, Agnete Gulati², Mari Hoff³ and Arthur Kavanaugh⁴, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Rheumatology, St.Olavs Hospital, Trondheim, Norway, ³Rheumatology, St Olavs Hospital, Trondheim, Norway, ⁴University of California San Diego, San Diego, CA
Background/Purpose: The use of TNF-inhibitors in psoriatic arthritis (PsA) has been shown to improve clinical and radiographic outcome in randomized controlled trials (RCT) and shown…
Abstract Number: 495 • 2013 ACR/ARHP Annual Meeting
The Impact Of Inadequate Response To Prior Biologic Agents On Abatacept Drug Retention In Rheumatoid Arthritis Patients. A Pan-European Analysis Of RA Registries
Axel Finckh¹, Florenzo Iannone², Juan Gomez Reino³, David Neto⁴, Elisabeth Lie⁵, Piet van Riel⁶, Merete Lund Hetland⁷, Karel Pavelka⁸, Carl Turesson⁹, Xavier Mariette¹⁰ and Jacques-Eric Gottenberg¹¹, ¹Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ²D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, ³Rheumatology Department, Hospital Clínico de Santiago, Santiago de Compostela, Spain, ⁴Rheumatology, University of Geneva, Geneva, Switzerland, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ⁸Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁹Lund University, Malmö, Sweden, ¹⁰Paris-Sud University, Paris, France, ¹¹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France
Background/Purpose: In rheumatoid arthritis (RA), abatacept (ABA) may be used in biologic naïve patients (pts) or after failure to an anti-TNF or other biologic agents…
Abstract Number: 314 • 2013 ACR/ARHP Annual Meeting
Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio
Bente Glintborg^1,2, Bjorn Gudbjornsson^3,4, Niels Steen Krogh⁵, Emina Omerovic², Natalia Manilo⁶, Mette Holland-Fischer⁷, Hanne M. Lindegaard⁸, Anne Gitte Loft⁹, Henrik Nordin¹⁰, Laura Johnsen¹¹, Sussi Flejsborg Oeftiger¹², Annette Hansen¹³, Claus Rasmussen¹⁴, Gerdur Grondal¹⁵, Árni Jón Geirsson¹⁶ and Merete Lund Hetland^1,2,17, ¹The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ³Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁵ZiteLab ApS, Copenhagen, Denmark, ⁶Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, ⁷Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, ¹⁰Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, ¹¹Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Denmark, ¹²Department of Rheumatology, Køge Hospital, Køge, East Timor, ¹³Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ¹⁴Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, ¹⁵Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, ¹⁶Rheumatology, Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, ¹⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: International guidelines recommend that in psoriatic arthritis infliximab should be dosed with 5 mg/kg bodyweight every 8th week. Data on the use of lower…
Abstract Number: 1731 • 2013 ACR/ARHP Annual Meeting
Treatment Of Innate Immune Arthritis With a Toll-Like Receptor 7 Agonist Requires Type I Interferon
Maripat Corr¹, Tomoko Hayashi², Dennis A. Carson³, Howard Cottam⁴ and Joshua Yang³, ¹Medicine, Univ of California-San Diego, La Jolla, CA, ²Medicine, UCSD School of Medicine, La Jolla, CA, ³UCSD School of Medicine, La Jolla, CA, ⁴ucsd School of Medicine, La Jolla, CA
Background/Purpose: We previously demonstrated that repeated administration of the low molecular weight Toll-like receptor (TLR) 7 agonist (1V136) substantially reduces arthritic inflammation in mice. Here…
Abstract Number: 2270 • 2012 ACR/ARHP Annual Meeting
The DNA Methylome of Systemic Lupus Erythematosus (SLE) From Whole Peripheral Blood Mononuclear Cells (PBMCs)
Robert Shoemaker¹, Lou H. Bookbinder², David L. Boyle³, Gary S. Firestein⁴, Jonathan E. Lim⁵ and David W. Anderson⁶, ¹Bioinformatics, NexDx, Inc., San Diego, CA, ²Molecular Biology, NexDx, Inc., San Diego, ³Div of Rheum, UCSD School of Medicine, La Jolla, CA, ⁴Div of Rheumatology, UCSD School of Medicine, La Jolla, CA, ⁵Research and Development, NexDx, Inc., San Diego, ⁶Research and Development, NexDx, Inc., San Diego, CA
Background/Purpose: SLE is a disease where epigenetic mechanisms play a role. Methylation of DNA at CpG loci is known to influence the suppression or activation…
Abstract Number: 1909 • 2012 ACR/ARHP Annual Meeting
Use of Uric Lowering Therapies within a Large Health Care System
Robert A. Overman¹, Brian F. Mandell² and Chad L. Deal³, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Dept of Rheum/Immun NA10, The Cleveland Clinic, Cleveland, OH, ³Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Guidelines for initiating urate lowering therapy (ULT) in the treatment of gout recommend treatment to a target serum urate (SUA) level of ≤6mg/dl with…
Abstract Number: 1895 • 2012 ACR/ARHP Annual Meeting
Safety Competences Knowledge and Behavioural Skills of Patients Treated by Biologics in Rheumatology
Anne-Christine Rat¹, Bruno Fautrel², Elisabeth Flipon³, Laure Gossec⁴, Benoit-Damien Caritey⁵, Laurent Marguerie⁶, Henri Nataf⁷, Beatrice Pallot Prades⁸, Rose Marie Poilvert⁹, Valerie Royant¹⁰, Fathia Sadji¹¹, Christelle Sordet¹², Corinne Thevenot¹³ and Catherine Beauvais¹⁴, ¹CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ²Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ³Cochin hospital, Paris, France, ⁴Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁵Epidemiology, Université de lorraine, Nancy, France, ⁶Rheumatology department, Institut Calot, Berck, France, ⁷Mantes-la-Jolie, Mantes-la-Jolie, France, ⁸Rheumatology department, Saint Etienne university hospital, Saint Etienne, France, ⁹Rheumatology department, Saint Antoine Hospital, Paris, France, ¹⁰Chartres, Chartres, ¹¹Rheumatology department, Victor Jousselin Hospital, Dreux, France, ¹²Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹³Department of Internal Medicine, Laon hospital, Laon, France, ¹⁴Rhumatologie, Saint Antoine, Paris, France
Background/Purpose: Biologics are known to entail specific risks; therefore teaching patients safety skills, appropriate behaviours in situations of risks and what decisions to take in…
Abstract Number: 1715 • 2012 ACR/ARHP Annual Meeting
Imatinib Mesylate (Gleevec™) in the Treatment of Diffuse Cutaneous Systemic Sclerosis: Results of a 24 Month Open Label, Extension Phase
Jessica K. Gordon¹, Morgana L. Davids², Kamini Doobay², Jamie N. Mersten¹, Cynthia Magro³, Horatio F. Wildman⁴, Stephen L. Lyman⁵, Mary K. Crow⁶ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medicine/Rheumatology, Hospital for Special Surgery, New York, NY, ³Dermatopathology, Weill-Cornell Medical Center, New York, NY, ⁴Dermatology, Weill-Cornell Medical Center, New York, NY, ⁵Research, Hospital for Special Surgery, New York, NY, ⁶Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Imatinib mesylate (IM) has been shown to decrease fibrosis in preclinical models and is a treatment of interest for Systemic Sclerosis (SSc). We have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].